Nurix Therapeutics (NRIX) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Nurix Therapeutics (NRIX) overview

Nurix Therapeutics (NRIX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 84.0m and operating profit of USD -286m; the year-end share price was 17.68 USD and market capitalisation was USD 1,800m. Nurix Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Nurix Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 539mFY 2025
Share price17.68 USDFY 2025 year end
RevenueUSD 84.0mFY 2025
Operating profitUSD -286mFY 2025
Net earningsUSD -264mFY 2025
Market capitalisationUSD 1,800mFY 2025 year end

About Nurix Therapeutics

Nurix Therapeutics discovers and develops targeted protein degradation medicines for cancer and inflammatory diseases. Its clinical pipeline includes investigational degraders targeting BTK and CBL-B, while its preclinical work includes additional degraders and degrader antibody conjugates. Nurix also conducts partnered drug discovery programs with pharmaceutical companies, using its DEL-AI platform to identify and advance potential drug candidates.

Generate the Nurix Therapeutics report

Nurix Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Nurix Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Nurix Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.